📊 PCVX Key Takeaways
Is Vaxcyte, Inc. (PCVX) a Good Investment?
Vaxcyte is a pre-revenue biotech company incurring massive operating losses (-$345.9M) and burning cash at an unsustainable rate (-$280.6M annually). While the balance sheet is fortress-like with $3.0B equity and no debt, current fundamentals show zero revenue generation and depleting cash resources relative to burn rate, making near-term survival dependent on successful drug commercialization or dilutive financing.
Vaxcyte, Inc. Key Strengths (PCVX)
- Fortress balance sheet with $3.0B stockholders equity and minimal debt (0.00x D/E)
- Exceptional liquidity position with 7.49x current ratio and $260.8M cash reserves
- Low capital intensity ($2.1M capex) suggests lean operational structure for R&D stage
- Large asset base ($3.3B) provides some downside protection
PCVX Stock Risks: Vaxcyte, Inc. Investment Risks
- Pre-revenue/zero commercial traction with no path to profitability visible
- Annual cash burn of $280.6M against $260.8M cash position is unsustainable without additional funding
- Massive operating losses (-$345.9M) and negative margins indicate capital-intensive drug development phase
- Dilution risk high from inevitable future equity raises to fund continued operations
- Biotech execution risk: success entirely dependent on drug development, clinical trials, and FDA approval
- Negative ROE (-10.7%) and ROA (-9.6%) reflect shareholder value destruction
Key Metrics to Watch
- Cash runway and burn rate trend relative to clinical trial progress milestones
- Revenue generation from any approved or commercialized products
- Operating expense reduction efficiency and R&D productivity metrics
- Equity dilution from future capital raises and implied cost per share
- Phase progression of pipeline candidates and regulatory milestones
Vaxcyte, Inc. (PCVX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 7.49x current ratio provides a solid financial cushion.
PCVX Profit Margin, ROE & Profitability Analysis
PCVX vs Healthcare Sector: How Vaxcyte, Inc. Compares
How Vaxcyte, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Vaxcyte, Inc. Stock Overvalued? PCVX Valuation Analysis 2026
Based on fundamental analysis, Vaxcyte, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Vaxcyte, Inc. Balance Sheet: PCVX Debt, Cash & Liquidity
PCVX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Vaxcyte, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-4.14 indicates the company is currently unprofitable.
PCVX Revenue Growth, EPS Growth & YoY Performance
Vaxcyte, Inc. Dividends, Buybacks & Capital Allocation
PCVX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Vaxcyte, Inc. (CIK: 0001649094)
📋 Recent SEC Filings
❓ Frequently Asked Questions about PCVX
What is the AI rating for PCVX?
Vaxcyte, Inc. (PCVX) has an AI grade of D with 90% confidence, based on fundamental analysis of SEC EDGAR filings.
What are PCVX's key strengths?
Claude: Fortress balance sheet with $3.0B stockholders equity and minimal debt (0.00x D/E). Exceptional liquidity position with 7.49x current ratio and $260.8M cash reserves.
What are the risks of investing in PCVX?
Claude: Pre-revenue/zero commercial traction with no path to profitability visible. Annual cash burn of $280.6M against $260.8M cash position is unsustainable without additional funding.
What is PCVX's revenue and growth?
Vaxcyte, Inc. reported revenue of N/A.
Does PCVX pay dividends?
Vaxcyte, Inc. does not currently pay dividends.
Where can I find PCVX SEC filings?
Official SEC filings for Vaxcyte, Inc. (CIK: 0001649094) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is PCVX's EPS?
Vaxcyte, Inc. has a diluted EPS of $-2.30.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is PCVX's fundamental grade?
Based on our AI fundamental analysis in June 2026, Vaxcyte, Inc. has a D grade with 90% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is PCVX stock overvalued or undervalued?
Valuation metrics for PCVX: ROE of -10.7% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is PCVX's AI grade for 2026?
Our dual AI analysis gives Vaxcyte, Inc. a combined D grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is PCVX's free cash flow?
Vaxcyte, Inc.'s operating cash flow is $-280.6M, with capital expenditures of $2.1M.
How does PCVX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -10.7% (avg: 15%), current ratio 7.49 (avg: 2).